Skip to main content
OpenTrials
Recruiting

NCT Number: NCT07460700

Mesenteric Ischemia Markers Study

Vascular bowel disease remains a socially significant and potentially fatal condition (if it develops into AMI), primarily due to delayed diagnosis. Blood biomarkers are theoretically ideal for early risk stratification (like troponins in myocardial infarction). However, the existing evidence base is characterized by low quality and high heterogeneity, which hinders their use in clinical practice. Therefore, there is an urgent and unmet clinical need for high-quality, methodologically rigorous research to validate biomarkers in MI. A current study (MESMARK) is to be undertaken to identify combinations of biomarkers that can reliably identify mesenteric ischemia (MI) and distinguish between non-transmural and transmural clinical relevant ischemia.

Recruiting

Interested in participating?

Request Info

Key information

Conditions

Mesenteric Vascular Disease Cardiovascular Diseases Digestive System Diseases Gastrointestinal Diseases Intestinal Diseases Mesenteric Ischemia Peritoneal Diseases Vascular Diseases

Age range

18 year and older

Sex eligibility

All sexes

Study type

Interventional

Phase

Not applicable

Primary location

Belarusian State Medical University

Minsk, Belarus

Location status: Recruiting

Location contact

Hleb But-Husaim, PhD

CONTACT

[email protected]

+375256139407

Who can participate

Healthy volunteers accepted: Yes

Only the study team can determine whether someone qualifies for participation.

Inclusion criteria

  • 18 years or older, all sex
  • Initial decision, the presence of angio-visualisation of the MA and suspicion of mesenteric arteries diseases
  • Patient's consent to participate in the study
  • No pregnancy, no history of major operations on MA, the gastrointestinal tract and digestive organs (except appendectomy, endoscopic polypectomy).

Exclusion criteria

  • Consent declined by patient or relatives
  • Failure to meet inclusion criteria

Treatment and study plan

Blood samples

Diagnostic Test

Blood samples as diagnostic tests are the only intervention in the trial

Primary outcomes

  1. Increasing in the level of mesenteric ischemia (MI) markers above the reference threshold level within 1 day after enrollment in the study

    Time frame: From enrollment to the 24 hours

    Assessment of serum markers level is intended to identify reliable serum markers or the panel of them as biomarkers for the diagnosis of MI. The endpoint is "increasing in serum marker level above the threshold reference level within 24 hours of objectively suspected MI or not". Markers with elevated above the reference threshold level will be assessed individually and in combination (as a marker panel) later to calculate their sensitivity and specificity in diagnostic of MI. These markers include intestinal fatty acid-binding protein (I-FABP), alpha-glutathione S-transferase (α-GST), ischaemia-modified albumin (IMA), D-lactate, D-dimer, adropin, hypoxia-inducible factor (HIF-1α).

Study contacts

Contact information is provided by the study sponsor or research team.

Hleb But-Husaim, PhD

CONTACT

[email protected]

+375256139407

Sponsors and collaborators

Lead sponsor

Belarusian State Medical University

Other

Registry information

Official study title

Mesenteric Ischemia Markers Study In The Presence Of Mesenteric Arteries Disease

Acronym: MESMARK

Important dates

Study start
2025
Primary completion
2026
Study completion
2026
First posted
Mar 10, 2026
Registry last updated
Mar 10, 2026

OpenTrials presents study information sourced from ClinicalTrials.gov. The official registry record should be consulted for the latest information.

View the official ClinicalTrials.gov record (opens in a new tab)

This listing is for discovery and informational purposes only. It is not medical advice, does not guarantee that a study is recruiting, and does not determine eligibility. Contact the study team and a qualified healthcare professional when considering participation.

Related clinical trials

Published trials that share one or more normalized conditions with this study.